Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 347-349

  Yin, Guozhu ^a   Bai, Yun ^a   Luo, En ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ANGIOGENESIS SUPPRESSION; ARTICLE; BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BONE REMODELING; CELL STIMULATION; GENE REPRESSION; HUMAN; HYPOTHESIS; JAW OSTEONECROSIS; OSTEOCLAST; PATHOGENESIS; PATHOPHYSIOLOGY;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; HUMANS; JAW; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOCLASTS; OSTEONECROSIS;

EID: 79751533399     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.10.036     Document Type: Article

References (32)

1. Rogers M.J., Watts D.J., Russell R.G. Overview of bisphosphonates. Cancer 1997, 80:1652-1660.
2. Boivin G., Meunier P.J. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2002, 2:538-543.
3. Licata A.A. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005, 39:668-677.
4. Van Beek E.R., Lowik C.W., Papapoulos S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002, 30:64-70.
5. Merlotti D., Gennari L., Martini G., Valleggi F., De Paola V., Avanzati A., et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone Miner Res 2007, 22:1510-1517.
6. Patel V, McLeod NM, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw-a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 2010;48. doi:10.1016/j.bjoms.2010.05.007. doi:10.1016/j.bjoms.2010.05.007.
7. Truong S.V., Chang L.C., Berger T.G. Bisphosphonate-related osteonecrosis of the jaw presenting as a cutaneous dental sinus tract: a case report and review of the literature. J Am Acad Dermatol 2010, 62:672-676.
8. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L.O. Steonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527-534.
9. Ruggiero S.L., Dodson T.B., Assael L.A., Landesberg R., Marx R.E., Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009, 67:2-12.
10. Ruggiero S.L., Woo S.B. Biophosphonate-related osteonecrosis of the jaws. Dent Clin North Am 2008, 52:111-128.
11. Cartsos V.M., Zhu S., Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc 2008, 139:23-30.
12. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
13. Jadu F., Lee L., Pharoah M., Reece D., Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007, 18:2015-2019.
14. Wang E.P., Kaban L.B., Strewler G.J., Raje N., Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007, 65:1328-1331.
15. Marx R.E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
16. Hansen T., Kunkel M., Weber A., James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006, 35:155-160.
17. Hansen T., Kunkel M., Springer E., Walter C., Weber A., Siegel E., et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007, 451:1009-1017.
18. Marx R.E., Pamidronate A., Zoledronate Z. Induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117.
19. Allen M.R., Burr D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009, 67:61-70.
20. Guise T.A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008, 34(Suppl. 1):S19-S24.
21. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008, 34(Suppl. 1):S25-S30.
22. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
23. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
24. Estilo C.L., Fornier M., Farooki A., Carlson D., Bohle G., Huryn J.M. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008, 26:4037-4038.
25. Cackowski F.C., Anderson J.L., Patrene K.D., Choksi R.J., Shapiro S.D., Windle J.J., et al. Osteoclasts are important for bone angiogenesis. Blood 2010, 115:140-149.
26. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25:4257-4266.
27. Findlay D.M., Haynes D.R. Mechanisms of bone loss in rheumatoid arthritis. Mod Rheumatol 2005, 15:232-240.
28. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001, 16:1575-1582.
29. Tanaka Y., Abe M., Hiasa M., Oda A., Amou H., Nakano A., et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 2007, 13:816-823.
30. Kiesel J., Miller C., Abu-Amer Y., Aurora R. Systems level analysis of osteoclastogenesis reveals intrinsic and extrinsic regulatory interactions. Dev Dyn 2007, 236:2181-2197.
31. Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633.
32. Wang Y., Wan C., Deng L., Liu X., Cao X., Gilbert S.R., et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007, 117:1616-1626.